Zealand Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Adam Steensberg

Chief executive officer

kr.10.0m

Total compensation

CEO salary percentage	30.6%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	2yrs
Board average tenure	11.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Adam Steensberg's remuneration changed compared to Zealand Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	-kr.1b
Jun 30 2022	n/a	n/a	-kr.1b
Mar 31 2022	n/a	n/a	-kr.957m
Dec 31 2021	kr.10m	kr.3m	-kr.1b
Sep 30 2021	n/a	n/a	-kr.925m
Jun 30 2021	n/a	n/a	-kr.1b
Mar 31 2021	n/a	n/a	-kr.909m
Dec 31 2020	kr.7m	kr.3m	-kr.847m
Sep 30 2020	n/a	n/a	-kr.660m
Jun 30 2020	n/a	n/a	-kr.545m
Mar 31 2020	n/a	n/a	-kr.624m
Dec 31 2019	kr.7m	kr.3m	-kr.572m

Compensation vs Market: Adam's total compensation ($USD1.43M) is about average for companies of similar size in the German market ($USD1.56M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.

CEO

Adam Steensberg (48 yo)

less than a year

Tenure

kr.9,975,000

Compensation

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Adam Steensberg	President & CEO	less than a year	kr.9.98m	no data
Henriette Wennicke	Chief Financial Officer	less than a year	no data	no data
Ivan Moller	Chief Operating Officer	4.8yrs	no data	no data
Lani Morvan	Investor Relations & Communications Officer	no data	no data	no data
Mads Kronborg	Head of Investor Relations & Communication	2.3yrs	no data	no data
Ravinder Chahil	Senior VP & General Counsel	less than a year	no data	no data
Christina Bredal	Senior VP and Global Head of People & Organization	1.7yrs	no data	no data
Hanne Bak	Senior Project Director	no data	kr.133.00k	no data
Jens Mikkelsen	Head of Molecular Pharmacology	no data	no data	no data
Danilo Verge	Head of Global Medical Affairs	2.3yrs	no data	no data
David Kendall	Chief Medical Officer	2.3yrs	no data	no data
Lykke Romer	VP & Head of Finance and Accounting	no data	no data	no data

2.0yrs

Average Tenure

50yo

Average Age

Experienced Management: 22ZA's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hanne Bak	Senior Project Director	6.7yrs	kr.133.00k	no data
Leonard Kruimer	Independent Director	3.7yrs	kr.861.00k	0.0078% DKK 105.3k
Alain Munoz	Co-Chair of the Clinical & Scientific Advisory Board & Director	15.9yrs	kr.723.00k	0.010% DKK 138.3k
Alf Gunnar Nicklasson	Independent Chairman of the Board	7.7yrs	kr.1.21m	0.0050% DKK 67.6k
Kirsten Drejer	Independent Vice Chairman	4.7yrs	kr.654.00k	0.0015% DKK 21.0k
Ake Lernmark	Member of Advisory Board	11.1yrs	no data	no data
Gudmund Korsgard	Board Observer	no data	no data	no data
Michael Owen	Independent Director	10.9yrs	kr.723.00k	0.00058% DKK 7.9k
Bernard Charbonnel	Member of Advisory Board	11.1yrs	no data	no data
Richard Pratley	Member of Advisory Board	11.1yrs	no data	no data
Paul Dorian	Member of Advisory Board	11.1yrs	no data	no data
Gert Van Assche	Member of Advisory Board	11.1yrs	no data	no data

11.1yrs

Average Tenure

68yo

Average Age

Experienced Board: 22ZA's board of directors are seasoned and experienced ( 11.1 years average tenure).

Zealand Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Recent updates

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Zealand Pharma Announces CEO Changes

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age